Exhibit 10.14


 




CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED PURSUANT TO ITEM 601(B)(10)(iv) BECAUSE
IT IS BOTH (i) NOT MATERIAL AND (ii) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.






 


LIPELLA PHARMACEUTICALS
INC.

NOTE CANCELLATION AND STOCK PURCHASE AGREEMENT


 


THIS NOTE CANCELLATION
AND STOCK PURCHASE AGREEMENT (the “Agreement”) is made as of the Effective Time (as defined herein) by
and between Dr. Michael Chancellor (the “Investor”) and Lipella Pharmaceuticals Inc., a Delaware corporation
(the “Company” and together with the Investor, the “Parties” or each, a “Party”).
For the purposes of this Agreement, the “Effective Time” shall mean immediately prior to the consummation of
the Company’s intended initial public underwritten offering.


 


WHEREAS, the
Company previously issued to the Investor (i) that certain promissory note, dated August 21, 2009, in the original principal amount
of $25,000, and (ii) that certain promissory note, dated January 25, 2015, in the original principal amount of $50,000 (collectively,
the “Promissory Notes”);


 


WHEREAS, in
consideration for the Investor agreeing to the Company’s cancellation of the Promissory Notes, the Company desires to issue
to the Investor, and the Investor desires to subscribe for and accept, that number of shares of the Company’s common stock,
par value $0.0001 per share (the “Common Stock”), as calculated pursuant to Section 1(b) of this Agreement (the
“Shares”); and


 


WHEREAS, the
Parties desire that the issuance of the Shares be, and be deemed for all purposes, full satisfaction for all of the Company’s
obligations under the Promissory Notes.


 


NOW, THEREFORE,
in consideration of the issuance of the Shares and the cancellation of the Promissory Notes, and of the mutual covenants and
other agreements contained in this Agreement, the Parties hereby agree as follows:


 


1.            Cancellation
of Promissory Notes and Issuance of Shares.


 


(a)           As
of the Effective Time and notwithstanding anything to the contrary set forth in any of the Promissory Notes, (i) the Promissory
Notes shall be terminated and canceled and shall be deemed null and void and of no further effect, and the Investor shall tender
the Promissory Notes to the Company, (ii) all obligations of the Company under each of the Promissory Notes shall be considered
fully satisfied in all respects, and such Promissory Notes shall no longer be deemed indebtedness or liabilities of the Company,
(iii) that all rights held by the Investor pursuant to each of the Promissory Notes shall be deemed terminated and no default shall
be declared by the Investor on either of the Promissory Notes, and (iv) that any and all principal and accrued interest due and
owed by the Company to the Investor pursuant to each of the Promissory Notes shall no longer be deemed owed to the Investor or
outstanding.


 


(b)           The
Investor hereby subscribes for, and, at the Effective Time, the Company shall cause its transfer agent to issue and deliver, that
number of shares of Common Stock equal to the result of (i) the principal and accrued interest due and owing by the Company to
the Investor at the Effective Time under the Promissory Notes divided by (ii) the initial public offering price per share
of the Common Stock (or if such offering is for units of the Company or a combination of Common Stock and other Company securities,
the price per unit or combined price for such Common Stock and other securities, as applicable) in the Company’s intended
initial public underwritten offering. The Company shall deem such issuance of Shares to be recorded on the books and records of
the Company.


 


(c)           The
Investor shall be responsible for any federal, state or local income or similar taxes required to be paid by the Investor with
respect to the Promissory Notes, the Shares and this Agreement. The Investor shall indemnify and hold the Company and each of its
directors, officers, and other affiliates harmless from and against any claim, demand, action, cause of action, loss, liability,
damage, cost, penalty or expense whatsoever, including reasonable and documented legal fees, suffered or incurred by the Company
or its directors, officers and other affiliates by reason of the Investor’s failure to pay or discharge any federal, state
or local income or similar taxes required to be paid by the Investor resulting from any amount paid or deemed to be paid to the
Investor.


 






     


     


    

 


(d)           All
such actions necessary to release any existing security interest on the Company’s assets, if applicable, shall be taken by
the Parties, including, but not limited to, making all requisite filings pursuant to the Uniform Commercial Code.


 


2.            Representations
and Warranties of the Investor. Investor acknowledges that the Shares have not been registered under the Securities Act of
1933, as amended (the “Act”), in reliance upon certain exemptions from registration under the Act. In connection
therewith, the Investor represents and warrants to the Company as follows:


 


(a)           The
Investor either has a preexisting personal or business relationship with the Company or its officers, directors or controlling
persons, or by reason of its business or financial knowledge and experience or the business or financial experience of its professional
advisors who are unaffiliated with and who are not compensated by the Company or any affiliate or selling agent of the Company,
directly or indirectly, could be reasonably assumed to have the capacity to protect his own interests in connection with the transaction
contemplated by this Agreement. The Investor is an “accredited investor” as defined in Regulation D promulgated under
the Act and has the legal capacity to execute, deliver and perform his obligations under this Agreement. The Investor is not subject
to any “bad actor” disqualifications described in Rule 506(d)(l)(i) to (viii) promulgated under the Act (a “Disqualifying
Event”), except for any Disqualifying Event covered by Rule 506(d)(2) or (d)(3) promulgated under the Act.


 


(b)           The
Investor recognizes that an investment in the Company involves substantial risks. The Investor understands and assumes all of the
risks related to the subscription for the Shares. The Investor acknowledges that it has successfully considered and has, to the
extent the Investor believes such discussion necessary, discussed with the Investor’s professional, legal, financial and
tax advisers, the suitability of an investment in the Shares for the Investor’s particular financial and tax situation and
has determined that an investment in the Shares is a suitable investment for him.


 


(c)           The
Company has provided the Investor and his representative, if any, prior to the purchase of the Shares, with the opportunity to
ask questions of, and receive answers from, representatives of the Company concerning the financial data and business of the Company
and to obtain any additional information relative to the financial data and business of the Company, and all such questions, if
asked, have been answered satisfactorily and all such documents, if examined, have been found to be fully satisfactory by the Investor.
The Investor is satisfied that he has received adequate information concerning all matters which he considers material to a decision
to purchase the Shares.


 


(d)           The
Investor understands that no offering statement, prospectus, memorandum or circular containing information with respect to the
Company or this subscription for the Shares has been or is to be prepared, and the Investor has made his own inquiry and analysis
with respect to the Company and the Shares, and that no public market currently exists for the Shares or the Common Stock. The
Investor acknowledges receiving a copy of all documents he has requested to his satisfaction. The Investor acknowledges that neither
the Company nor any director or officer of the Company has participated in, has any responsibility for, or makes any representations
or warranties regarding the contents of any document or any omissions therefrom. The Investor acknowledges that no federal or state
agency has approved or disapproved of the issuance of the Shares, passed upon or endorsed the merits of such subscription for the
Shares, or made any finding or determination as to the fairness of the terms of such subscription. The Investor acknowledges that
no action has been or will be taken in any jurisdiction outside the United States by the Company that would permit an offering
of the Shares, or possession or distribution of offering materials in connection with the issue of the Shares in any jurisdiction
outside the United States where action for that purpose is required and if the Investor is outside the United States, he will comply
with all applicable laws and regulations in each foreign jurisdiction in which he purchases, offers, sells or delivers the Shares
or has in his possession or distributes any offering material, in all cases at his own expense.


 






     


     


    

 


(e)           The
Investor represents and warrants to the Company that he is acquiring the Shares for his own account, for investment only, and not
with a view to, or for resale in connection with, any distribution thereof. The Investor represents and warrants that he does not
have any present intention of selling or otherwise transferring the Shares or any interest therein. The Investor acknowledges and
agrees that the Shares may not be sold, transferred, pledged or otherwise disposed of without registration under the Act and applicable
state securities laws or in accordance with applicable exemptions therefrom. The Investor represents that, except as set forth
below, it is not a e Financial Industry Regulatory Authority, Inc. (“FINRA”) member or an Associated Person
(as such term is defined under FINRA’s rules and regulations).


 


(f)           The
Investor acknowledges that no representations, warranties, covenants or promises have been made concerning the marketability or
value of the Shares or of the Common Stock. The Company has not agreed with, represented or covenanted to the Investor that the
Shares will be purchased or redeemed from the Investor at any time in the future. There have been no representations, warranties,
promises, covenants or agreements that the Common Stock will be registered under the Act at any specific time in the future or
otherwise qualified for sale under applicable securities laws. The Investor acknowledges that he may be required to bear the economic
risk of an investment in the Common Stock for an indefinite period of time.


 


(g)           The
Investor represents that the foregoing representations and warranties are true and correct as of the Effective Time and, unless
the Investor otherwise notifies the Company in writing prior to the Closing Date, shall be true and correct as of the Closing Date.


 


(h)           Restrictive
Legends. The Shares, once issued, shall bear the following legend or a substantially similar legend:


 


“THE
ISSUANCE AND SALE OF THE SHARES OF COMMON STOCK OF LIPELLA PHARMACEUTICALS INC. (THE “COMPANY”) REPRESENTED BY THIS
CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), NOR APPLICABLE STATE
SECURITIES LAWS. SUCH SHARES OF COMMON STOCK MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A)
AN EFFECTIVE REGISTRATION STATEMENT FOR SUCH SHARES OF COMMON STOCK UNDER THE ACT, OR (B) AN OPINION OF COUNSEL (WHICH COUNSEL
SHALL BE SELECTED BY THE HOLDER AND REASONABLY APPROVED BY THE COMPANY), IN A GENERALLY ACCEPTABLE FORM, THAT REGISTRATION IS NOT
REQUIRED UNDER SAID ACT OR (II) UNLESS SOLD PURSUANT TO RULE 144 OR RULE 144A UNDER THE ACT. NOTWITHSTANDING THE FOREGOING, SUCH
SHARES OF COMMON STOCK MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN OR FINANCING ARRANGEMENT SECURED
BY SUCH SHARES OF COMMON STOCK.”


 


(i)           Transfer
Restrictions. The Investor understands and acknowledges that the Investor and the Shares may be subject to the terms of (i)
the Shareholders Agreement, dated May 16, 2005, by and among the signatories thereto, and (ii) a lock-up agreement that may be
entered into by the Investor with the representative of the underwriters for the Company’s intended initial public offering,
each of which may restrict the Investor’s ability to sell, offer to sell, assign, pledge, hypothecate or otherwise transfer
any of the Shares. The Investor further understands and acknowledges that the Shares may not be sold, offered, assigned, pledged,
hypothecated or otherwise transferred unless pursuant to an effective registration statement under the Act or unless an exemption
from registration or safe harbor is available.


 






     


     


    

 


3.            Representations
and Warranties of the Company. The Company hereby represents and warrants to the Investor as follows:


 


(a)           Organization,
Good Standing, Corporate Power and Qualification. The Company is a corporation duly organized, validly existing and in good
standing under the laws of the State of Delaware and has all requisite corporate power and authority to carry on its business as
presently conducted and as proposed to be conducted.


 


(b)           Authorization.
All corporate action required to be taken by the Company in order to authorize the Company to enter into this Agreement, and to
issue the Shares, has been taken or will be taken prior to the Effective Time. All action on the part of the officers of the Company
necessary for (i) the execution and delivery of this Agreement, (ii) the performance of all obligations of the Company under this
Agreement, and (iii) the issuance and delivery of the Shares has been taken prior to the Effective Time. This Agreement, when executed
and delivered by the Company, shall constitute a valid and legally binding obligation of the Company, enforceable against the Company
in accordance with its terms except (x) as limited by applicable bankruptcy, insolvency, reorganization, moratorium, fraudulent
conveyance, or other laws of general application relating to or affecting the enforcement of creditors’ rights generally,
or (y) as limited by laws relating to the availability of specific performance, injunctive relief, or other equitable remedies.


 


(c)           Valid
Issuance of the Shares. The Shares to be issued to the Investor, when issued and delivered in accordance with the terms and
for the consideration set forth in this Agreement, will be validly issued, fully paid and nonassessable shares of Common Stock
and free of restrictions on transfer other than the pursuant to Section 2(i) of this Agreement. Neither the Company nor any party
acting on its behalf has offered or sold the Shares to the Investor by any form of general solicitation, general or public media
advertising or mass mailing.


 


(d)           Governmental
Consents and Filings. Assuming the accuracy of the representations and warranties of the Investor in Section 2 of this Agreement,
no consent, approval, order or authorization of, or registration, qualification, designation, declaration or filing with, any federal,
state or local governmental authority is required on the part of the Company in connection with the consummation of the transactions
contemplated by this Agreement.


 


(e)           No
Other Representations or Warranties. Except for the representations and warranties made by the Company in this Agreement (the
“Company Representations”), neither the Company nor any other party makes any representation or warranty with
respect to the Company or its business, operations, assets, liabilities, condition (financial or otherwise) or prospects, notwithstanding
the delivery or disclosure to the Investor or its representatives of any documentation, forecasts or other information with respect
to any one or more of the foregoing, and Investor is relying solely on the Company Representations in its execution, delivery and
performance of this Agreement.


 


4.           Survival
and Indemnification. The terms of this Agreement or any other documents executed and delivered in connection therewith, and
including, without limitation, the indemnification contained in this Section 4, shall survive (i) the acceptance of this Agreement
by the Company, (ii) changes in the transactions, documents and instruments described herein, and (iii) the death, disability or
dissolution of the Investor. The Investor acknowledges the meaning and legal consequences of the representations, warranties and
covenants in determining the Investor’s qualification and suitability to subscribe for and acquire the Shares. The Investor
hereby agrees to indemnify, defend and hold harmless the Company, and its officers, directors, employees, agents and controlling
persons, from and against any and all direct losses, claims, damages, liabilities, expenses (including attorneys’ fees and
disbursements), judgments or amounts paid in settlement of actions arising out of or resulting from the untruth of any representation
herein or the breach of any warranty, covenant or acknowledgment made herein by the Investor.


 






     


     


    

 


5.           Assignability;
Waiver. This Agreement is not assignable by the Investor and may not be waived or terminated except by an instrument in writing
signed by the party against whom enforcement of such waiver or termination is sought.


 


6.           Entire
Agreement. This Agreement constitutes the entire agreement of the Parties relating to the matters contained herein, superseding
the Promissory Notes and all other prior contracts or agreements, whether oral or written.


 


7.           Governing
Law. This Agreement shall be governed and controlled as to the validity, enforcement, interpretation, construction and effect
and in all other aspects by the substantive laws of the State of Delaware, without reference to conflicts of laws principles.


 


8.           Severability.
If any provision of this Agreement or the application thereof to any circumstance shall be held invalid or unenforceable to any
extent, the remainder of this Agreement and the application of such provision to other subscriptions or circumstances shall not
be affected thereby and shall be enforced to the greatest extent permitted by law.


 


9.           Headings.
The headings in this Agreement are inserted for convenience only and are not intended to describe, interpret, defined, or limit
the scope, extent or intent of this Agreement or any provision hereof.


 


10.         Counterparts.
This Agreement may be executed in any number of original or electronic counterparts, each of which when so executed and delivered
shall be deemed to be an original and all of which together shall be deemed to be one and the same agreement. A signature to this
Agreement transmitted electronically shall have the same authority, effect, and enforceability as an original signature.


 


11.         Amendment
and Modification. This Agreement may be amended or modified, or any provision hereof may be waived, provided that such amendment
or waiver is set forth in writing executed by each of the Parties. No course of dealing between or among any parties having any
interest in this Agreement will be deemed effective to modify, amend or discharge any part of this Agreement or any rights or obligations
of any other party under or by reason of this Agreement.


 


12.         Jurisdiction.
The Investor hereby irrevocably consents, to the maximum extent permitted by law, that any legal action or proceeding against him
by the Company, arising out of or in any manner relating to this Agreement shall be brought exclusively in either the New York
Supreme Court, County of New York, or in the United States District Court for the Southern District of New York. By its execution
and delivery of this Agreement, the Investor expressly and irrevocably consents and submits to the personal jurisdiction and jurisdiction
over his property of all of such courts in any such action or proceeding. The Investor expressly and irrevocably waives his claims
and defenses in any such action or proceeding in any of such courts based on any alleged lack of personal jurisdiction, improper
venue or forum non conveniens or any similar basis to the maximum extent permitted by law.


 


13.         Binding
Effect. This Agreement shall be binding upon the Investor and the heirs, personal representatives, successors and permitted
assigns of the Investor (provided that this Agreement and the rights and obligations of the Investor hereunder are not transferable
or assignable by the Investor).


 


14.         Termination.
If the Effective Time has not occurred on or before 11:59 PM, New York City time, on December 31, 2022 (the “Termination
Time”), then this Agreement shall terminate automatically, effective as of the Termination Time, and the Promissory Notes
shall remain outstanding.


 


[Signature Page Follows]


 




     


     


    

 


IN WITNESS WHEREOF, each of the undersigned Parties have executed this Agreement as of the date indicated above.


 





	Dr. Michael Chancellor	 	/s/ Michael Chancellor
	Investor’s Full Legal Name	 	Signature of Investor
	 	 	 
	[***]	 	[***]
	Address	 	Email Address
	 	 	 
	[***]	 	[***]
	City, State, Zip Code	 	U.S. Social Security or Taxpayer I.D. No.

(if Applicable)
	 	 	 
	[***]	 	 
	Telephone Number	 	 



   



Please Check Appropriate
Category:


 


_X_ Individual  


 


___  Tenants in Common  


 


___  Joint tenants with right of survivorship  


 


___  As custodian, trustee or agent for:  


 


___  Other
(e.g., corporation, Company, etc.)  


 



	AGREED TO AND ACCEPTED
    BY:	 	SHARE SUBSCRIBED FOR:
	 	 	 
	LIPELLA PHARMACEUTICALS INC.	 	 
	 	 	 
	By:	Jonathan
    Kaufman	 	Number of Shares: 22,950
	 	 	 	 
	Its:	Chief
    Executive Officer